IDH mutations are prevalent in several other rare malignancies, such as glioma, acute myeloid leukemia, and thyroid carcinoma, so that multiple IDH-selective inhibitors have been developed [86]. This evidence concerns the gene IDH1 and thyroid gland carcinoma.